The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Paris, February 23rd, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 […]
Press Releases
February 23, 2017
Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I
February 7, 2017
Acticor Biotech Secures €1,5M new funding from CapDecisif Management
To accelerate the clinical study of ACT-017, for the emergency treatment of stroke Paris, February 7th 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total […]
October 14, 2016
Stroke company Acticor Biotech and Mediolanum announce a Research Collaboration Agreement
For ACT017, a « first in class » antithrombotic treatment for Acute Ischemic Stroke. Paris, Milan, on October 14, 2016 – Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum […]
July 11, 2016
€1.4 million capital increase by Acticor Biotech
Funding used to step up development of its first-in-class drug candidate for the emergency treatment of strokes Paris, 11 July 2016 – Acticor Biotech, biotechnology company agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform which is […]
March 2, 2016
Acticor Biotech selects Catalent GPEx® Cell Line Development Technology to develop ACT017
Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes. Paris, March 1st, 2016 – Acticor Biotech today announced that it selected Catalent’s proprietary GPEx® technology for the development of its Fab candidate, ACT017, targeting the platelet glycoprotein VI (GPVI). The […]
January 26, 2015
Acticor Biotech bets on crowdfunding for health and successfully raises its first seed round
The company is seeking to develop a monoclonal antibody with antiplatelet activity as a first line emergency treatment of stroke. Paris, January 26th, 2015, Acticor Biotech, a biotech company dedicated to the development of an emergency treatment of ischemic stroke, announced today the successful closing of its first capital increase for a total of €590,000. […]